MorphoSys AG To Present At Upcoming Investor Conferences
PLANEGG, MUNICH, GERMANY / ACCESSWIRE / August 10, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) will present at the following conferences:
Commerzbank Sector Conference
Date: August 29, 2017
Venue: Frankfurt, Germany
Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
MorphoSys Capital Markets Day
Date: September 5 and 6, 2017
Venue: London, UK and New York, USA
Participants: Management Board of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Goldman Sachs 7th Annual Biotech Symposium
Date: September 8, 2017
Venue: London, UK
Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Berenberg and Goldman Sachs Sixth German Corporate Conference
Date: September 18, 2017
Venue: Munich, Germany
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
Baader Investment Conference
Date: September 20, 2017
Venue: Munich, Germany
Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR
A PDF version of all presentations and, where available, a webcast link to the respective event will be available at www.morphosys.com.
About MorphoSys:
MorphoSys’s mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders.
Based on its proprietary technology platforms, particularly in the field of fully human therapeuc antibodies, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development.
In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs’ further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
SOURCE: MorphoSys AG
ReleaseID: 472118
Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com